New possibilities of therapy in patients with non-alcoholic steatohepatitis with sublingual form of ademetionine
Summary. The article presents a modern view on the etiopathogenesis of non-alcoholic fatty liver disease as a hepatic manifestation of the metabolic syndrome, in which the liver is one of the main target organs. An advisability of addition to the therapy of sublingual form of ademetionine (the dietary supplement AGEPTA) in patients with non-alcoholic steatohepatitis are presented. It is shown that AGEPTA is a physiological and safe supplement in patients with non-alcoholic steatohepatitis and can be considered as an effective component of complex pathogenetic therapy in this patients.
Key words: non-alcoholic fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis, ademetionin, AGEPTA.